Annals of Case Reports and Clinical Studies (ISSN: 2834-5673) | Volume 3, Issue 3 | Case Report | Open Access DOI
Zumbolo Francesca*
Zumbolo F1*, Pugliese G1, de Alteriis G1, Muscogiuri G1, Barrea L2, Aprano S1, Laudisio D1, Cossiga V1, Morisco F3, and Savastano S1
1Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
2Department of Humanities, Telematic University Pegaso, Naples, Italy
3Department of Translational Medical Science, University of Naples "Federico II", Naples, Italy
*Correspondence to: Zumbolo Francesca
Fulltext PDFObjectives: Hyperphagia and severe obesity resistant to dietary interventions represent common clinical features of Prader Willi Syndrome (PWS). Currently, there are no drugs approved for the treatment of obesity in PWS patients. Liraglutide, a long-acting human Glucagon Like Peptide-1 (GLP-1) analogue, is an effective drug for the treatment of non-syndromic obesity. Here we describe a case of a young female patient with PWS affected by persistent hyperphagia and severe obesity resistant to previous weight loss attempts that was successfully treated with liraglutide.
Methods: Liraglutide was administered subcutaneously at a starting dosage of 0.6 mg/day, in weekly intervals until the dosage of 3 mg/day for 6 months in addition to a mild hypocaloric diet. Hyperphagia, assessed by Hyperphagia Questionnaire (HQ), Quality of Life (QoL), assessed by The Short Form-36 (SF-36), anthropometric measurements, metabolic profile, and liver steatosis/fibrosis indices, were evaluated at baseline and at 6 months.
Results: The score of hyperphagia dropped from 16 to 6. Percent Weight Loss (%WL) percent excess weight loss (%EWL) were 12% and 26%, respectively, and associated with improvements in insulin resistance, liver steatosis/fibrosis indices, resulting in the transition from advanced to mild fibrosis.
Conclusions: In our case report, treatment with liraglutide in addition to a mild hypocaloric diet resulted in improvements in hyperphagia, excess body weight, insulin resistance, and liver steatosis/fibrosis indices, which were not previously achieved after diet alone. Liraglutide could represent a valid therapeutic strategy for the management of hyperphagia and weight loss in patients with PWS.
Glucagon Like Peptide-1 analogue; Prader Willi Syndrome; liraglutide, hyperphagia, syndromic obesity
Zumbolo F, Pugliese G, de Alteriis G, Muscogiuri G, Barrea L, Aprano S, et al. Efficacy of Liraglutide in the Management of Hyperphagia, Severe Obesity, and Liver Steatosis/Fibrosis Indices in Prader Willi Syndrome: A Case Report. Ann Case Rep Clin Stud. 2024;3(3):1-2.